After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Stifel Reiterates Hold Rating on Tempus AI Inc (TEM)
February 25, 2025 9:09 AM ESTStifel analyst Daniel Arias reiterated a Hold rating and $65.00 price target on Tempus AI Inc (NASDAQ: TEM).
The analyst comments "4Q results were in line with the JPM pre-announcement, as revenues grew 36%. For FY25, the full business (core TEM + Ambry) matches... More
Hims and Hers (HIMS) PT Raised to $61 at Needham
February 25, 2025 6:07 AM ESTNeedham analyst Ryan MacDonald raised the price target on Hims and Hers (NYSE: HIMS) to $61.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We reiterate our Buy rating & raise our PT to $61 on HIMS following the company's strong 4Q... More
Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)
February 25, 2025 5:36 AM ESTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating and $24.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line: Fundamentally, HIMS' 4Q'24 results were slightly below what we think were buyside expectations. HIMS beat our/consensus revenue by ~1.2%/~2.2%,... More
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
February 25, 2025 5:35 AM ESTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $60.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "Weight loss, including personalized GLP-1 and oral meds, was guided to grow above the overall growth rate in 2025. This part of the... More
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
February 25, 2025 5:34 AM ESTTruist Securities analyst Jailendra Singh reiterated a Hold rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "Bottom Line. HIMS posted 4Q24 results with revenues slightly ahead of consensus and adjusted EBITDA in-line. However, compared to the broader investor expectations, results were below. Interestingly, the majority of beat in the quarter (relative to our estimate)... More
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21
February 25, 2025 5:17 AM ESTBofA Securities analyst Michael Cherny reiterated an Underperform rating and $21.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "HIMS 2025 revenue growth guidance embeds a significant level of optimism around two key items: 1) core revenue growth (ex-GLP-1s); and 2) a successful handoff between semaglutide and oral/liraglutide subscriptions into the second half of the... More
JPMorgan Downgrades Tempus AI Inc (TEM) to Neutral
February 25, 2025 5:13 AM ESTJPMorgan analyst Rachel Vatnsdal downgraded Tempus AI Inc (NASDAQ: TEM) from Overweight to Neutral with a price target of $55.00 (from $50.00).
The analyst comments "Tempus AI (TEM) reported 4Q results in-line with the pre-announcement from our conference (where revenue slightly missed expectations on non-core business weakness) while lifting its 2025 guidance, now calling for 2025 revenue of ~$1.24B inclusive of 11 months of Ambry (which closed on Feb. 3rd) vs. prior guide of ~$1.23B, along with adj. EBITDA of $5M this year vs.... More
BTIG Reiterates Buy Rating on Hims and Hers (HIMS)
February 25, 2025 5:11 AM ESTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "On Monday, 2/24/25 AMC, HIMS reported good 4Q:24 results. Revenue of $481.1M +95% y/y exceeded BTIG / consensus estimates of $474M / $470M and adjusted EBITDA... More
Hims and Hers (HIMS) PT Raised to $27 at Citi, Maintains Sell 'as we await a better entry point and more details on growth outside GLP-1s'
February 25, 2025 4:58 AM ESTCiti analyst Daniel Grosslight raised the price target on Hims and Hers (NYSE: HIMS) to $27.00 (from $25.00) while maintaining a Sell rating.
The analyst comments "The focus on HIMS 4Q earnings call (and our follow-up with mgmt.) was on the durability of HIMS weight loss... More
